Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1-Reference-Cited by-同舟云学术

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1

Published:2018-02 Issue: Volume:90 Page:122-129
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Haag G.M.,Zoernig I.,Hassel J.C.,Halama N.,Dick J.,Lang N.,Podola L.,Funk J.,Ziegelmeier C.,Juenger S.,Bucur M.,Umansky L.,Falk C.S.,Freitag A.,Karapanagiotou-Schenkel I.,Beckhove P.,Enk A.,Jaeger D.

Funder

Bristol-Myers Squibb

Federal Ministry of Education and Research

German research Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Systematic review of medical treatment in melanoma: current status and future prospects;Garbe;Oncol,2011

2. Immunology beats cancer: a blueprint for successful translation;Pardoll;Nat Immunol,2012

3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

4. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers;Frontiers in Immunology;2023-06-16

2. New Drug Development and Clinical Trial Design by Applying Genomic Information Management;Pharmaceutics;2022-07-24

3. A B‐cell or a key player? The different roles of B‐cells and antibodies in melanoma;Pigment Cell & Melanoma Research;2022-03-04

4. ANALYSIS OF CANCER-TESTIS ANTIGENS AS POTENTIAL MARKERS FOR DISSEMINATION OF PRIMARY HUMAN SKIN MELANOMA;Siberian journal of oncology;2021-06-29

5. Current Advances in the Treatment of BRAF-Mutant Melanoma;Cancers;2020-02-19